Schrödinger, Inc. (Nasdaq: SDGR) today announced the discontinuation of the clinical development program for SGR-2921, its ...

Programmed death-1 (PD-1) inhibition with pembrolizumab led to durable remission in 31.3% of patients with early acute ...

Schrödinger is abandoning its CDC7 inhibitor after the therapy was linked to the deaths of two patients in a phase 1 leukemia trial. The biotech had been evaluating the asset, dubbed SGR-2921, in an ...

Amir Fathi, MD, leukemia specialist at Massachusetts General Hospital, discusses the importance of advocacy by both patients ...

Schrodinger discontinued its study of a potential treatment for acute myeloid leukemia or high-risk myelodysplastic syndromes, citing patient deaths linked to the treatment.

Schrödinger is discontinuing the development of its blood cancer CDC7 inhibitor after two patient deaths. In a Phase I trial ...

Announced entry into an agreement to be acquired by XOMA Royalty Corporation for between $1.16 and $1.24 per share in cash, ...

Researchers sought to determine whether elderly, fit patients with AML would respond to therapy with venetoclax plus modified intensive chemotherapy.

Investing.com -- Schrodinger Inc (NASDAQ:SDGR) stock plunged 13.7% after the company announced it is discontinuing the clinical development program for its CDC7 inhibitor SGR-2921, which was being ...

Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in ...

Schrödinger has halted development of its cancer-fighting candidate SGR-2921 after two patients treated with the CDC7 inhibitor died in a Phase I trial.

LAVA Therapeutics ( ($LVTX) ) has issued an announcement. On August 13, 2025, LAVA Therapeutics announced its acquisition by XOMA Royalty ...